University of Hawai‘i at Manoa Homepage

Faculty

Jonathan K. Cho, MD

Jonathan K. Cho, MD
  • Clinical Professor
    Clinical and Translational Research Program
    University of Hawaii Cancer Center
  • Assistant Clinical Professor of Medicine
    John A. Burns School of Medicine, University of Hawaii at Manoa
  • Co-Medical Director of the Clinical and Translational Research Services SR
  • Private Practice, OnCare Hawaii, Inc. 
    Medical Oncology/Hematology

Degrees

  • MD
    John A. Burns School of Medicine
    University of Hawaii at Manoa

Research Focus

Dr. Cho has served as the Principal Investigator (PI) of the NCI-funded Hawaii Minority-Based Community Clinical Oncology Program (MBCCOP) at the University of Hawaii Cancer Center. He has been a faculty member of the UH Cancer Center since 1991. He has expanded the infrastructure of clinical trial activities at the UH Cancer Center allowing the conduct of both investigator-initiated translational sciences and pharmaceutical-sponsored trials. He is currently the PI of various pharmaceutical-sponsored oncology trials at the Cancer Center. He is also involved in developing the clinical trials activity of the Hawaii Cancer Consortium.

Selected Publications

  • Cho, J.K.. International Association for the Study of Lung Cancer- The Lung Cancer Staging Project, Hawaii Med J, 67(8) 220-222, 2008.
  • Cho, J.K.. Lung Cancer Treatment: Present and Future. Hawaii Med J, 63(2):61-2.2003.
  • Ross, H.J., Cho, J.K., Osann, K., Wong, S.P., et al. Phase I/II trial of low-dose Cyclosporin A with EP for advanced non-small-cell 1ung cancer. Lung Cancer, 1:1-10, 1997.
  • Cho, J.K., Lee, Y., Lutzky, J., Redpath, L., Slater, L. Collateral Sensitivity to Radiation and Cis-Platinum in a Multidrug Resistant Human Leukemia Cell Line. Cancer Chemotherapy Pharmacol. 37:168-172 (1995).
  • Singh, D., DoroshowJ.II., Leong, L., Margolin, K. Akman, S., Raschko, J., Somlo, G., Morgan. R., Harrison, J., Cho Cho, J.K., Ahn, C. Phase II Trial of 5-FIuorouracil, High-Dose Leucovorin, Calcium, and Dipyridamole in Advanced Prostate Cancer. Cancer Research Clinical Oncology, 119:117-120, 1992.

Publication list via PubMed

Active Trials

  • J. Cho, Principal Investigator
    A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER2- positive progressive or recurrent locally advanced or metastatic breast cancer (MBC)
    Pharmaceutical Sponsor: Roche/Genentech
  • J. Cho, Principal Investigator
    An Open-Label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)
    Pharmaceutical Sponsor: Abbott
  • J. Cho, Principal Investigator
    Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 in Standard of Care Chemotherapy (Premetrexed or Docetaxel) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus
    Pharmaceutical Sponsor: Pfizer
  • J. Cho, Principal Investigator
    Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus
    Pharmaceutical Sponsor: Pfizer
  • J. Cho, Principal Investigator
    Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2-Node-Positive and High-Risk Node-Negative Breast Cancer Patients to Prevent Recurrence
    Sponsor: US Department of Defense